Table 2.

Correlation between p-AKT and p-ERK1/2 expressions and clinicopathologic factors in 93 patients with STS

FactorsCategoryTotal no. patientsPatients with level 2 p-AKT expression (n = 26)PPatients with level 2 p-ERK1/2 expression (n = 6)P
Histologic classification1: Liposarcoma268 (30.8%)N.S.2 (7.7%)N.S.
2: Malignant fibrous histiocytoma289 (32.1%)2 (7.1%)
3: Leiomyosarcoma153 (20.0%)1 (6.7%)
4: Malignant neurogenic tumor72 (28.6%)0 (0%)
5: Synovial sarcoma103 (30.0%)1 (10.0%)
6: Rhabdomyosarcoma30 (0%)0 (0%)
7: Malignant vascular tumor10 (0%)0 (0%)
8: Extraskeletal chondrosarcoma20 (0%)0 (0%)
9: Extraskeletal osteosarcoma10 (0%)0 (0%)
Mitotic count1: ≤5/10 HPF5014 (28.0%)N.S.3 (6.0%)N.S.
2: 5-10/10 HPF236 (26.1%)2 (8.7%)
3: >10/10 HPF206 (30.0%)1 (5.0%)
Cellularity1: Low205 (25.0%)N.S.2 (10.0%)N.S.
2: Moderate3910 (25.6%)0 (0%)
3: High3411 (32.4%)4 (11.8%)
Cellular pleomorphism1: Minimal4111 (26.8%)N.S.5 (12.2%)N.S.
2: Moderate277 (25.9%)0 (0%)
3: Marked258 (32.0%)1 (4.0%)
Necrosis1: Absent to minimal6415 (23.4%)N.S.4 (6.3%)N.S.
2: Moderate144 (28.6%)1 (7.1%)
3: Marked157 (46.7%)1 (6.7%)
Sclerosis1: Absent to minimal7222 (30.6%)N.S.6 (8.3%)N.S.
2: Moderate131 (7.7%)0 (0%)
3: Marked83 (37.5%)0 (0%)
Myxoid change1: Absent to minimal5518 (32.7%)N.S.4 (7.3%)N.S.
2: Moderate183 (16.7%)2 (11.1%)
3: Marked205 (25.0%)0 (0%)
Ki-67 LI1: <20%5214 (26.9%)N.S.3 (5.8%)N.S.
2: ≥20%4112 (29.3%)3 (7.3%)
Age (y)54.9 ± 1.4855.9 ± 2.81N.S.58.0 ± 5.84N.S.
Gender1: Male5312 (22.6%)N.S.4 (7.5%)N.S.
2: Female4014 (35.0%)2 (5.0%)
Tumor location1: Upper extremity225 (22.7%)N.S.2 (9.1%)N.S.
2: Trunk215 (23.8%)2 (9.5%)
3: Lower extremity5016 (32.0%)2 (4.0%)
Tumor size1: ≤5 cm306 (20.0%)N.S.1 (3.3%)<0.05
2: 5-10 cm286 (21.4%)0 (0%)(1 and 2 vs 3)
3: >10 cm258 (32.0%)4 (16.0%)
Tumor depth1: superficial111 (9.1%)N.S.0 (0%)N.S.
2: deep7422 (29.7%)5 (6.7%)
Types of surgery1: Intralesional excision20 (0%)N.S.0 (0%)N.S.
2: Marginal excision3412 (35.3%)3 (8.8%)
3: Wide excision5513 (23.6%)3 (5.5%)
4: Amputation21 (50.0%)0 (0%)
Adjuvant chemotherapy1: Done4714 (29.8%)N.S.3 (6.4%)N.S.
2: Not done4612 (26.1%)3 (6.5%)
Adjuvant radiotherapy1: Done185 (27.8%)N.S.1 (5.6%)N.S.
2: Not done7521 (28.0%)5 (6.7%)
p-AKT expression1: Level 1672 (3.0%)<0.05
2: Level 2264 (15.4%)
p-ERK1/2 expression1: Level 18722 (25.3%)<0.05
2: Level 264 (66.7%)
p-FKHR expression1: Level 15211 (21.2%)<0.013 (5.8%)N.S.
2: Level 286 (75.0%)2 (25.0%)
  • Abbreviation: HPF, high-power field.